Comments
Loading...

Viridian Therapeutics

VRDNNASDAQ
Logo brought to you by Benzinga Data
$22.50
1.446.84%
At Close: -
$22.50
00.00%
After Hours: 4:00 PM EDT
15 minutes delayed
Consensus Rating1
Outperform
Highest Price Target1
$56.00
Lowest Price Target1
$20.00
Consensus Price Target1
$38.60

Viridian Therapeutics (NASDAQ:VRDN) Stock, Analyst Ratings, Price Targets, Forecasts

Viridian Therapeutics Inc has a consensus price target of $38.6 based on the ratings of 17 analysts. The high is $56 issued by BTIG on September 10, 2024. The low is $20 issued by B. Riley Securities on May 9, 2024. The 3 most-recent analyst ratings were released by RBC Capital, RBC Capital, and Goldman Sachs on September 19, 2024, September 13, 2024, and September 12, 2024, respectively. With an average price target of $39.67 between RBC Capital, RBC Capital, and Goldman Sachs, there's an implied 76.30% upside for Viridian Therapeutics Inc from these most-recent analyst ratings.

Analyst Trends and Forecast
1
Jun
1
Jul
2
Aug
2
Sep
Buy
Hold
Sell
Strong Sell
Analyst Rating and Forecast
12345
4.3
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

RBC Capital
Goldman Sachs
Needham
HC Wainwright & Co.
BTIG

1calculated from analyst ratings

Analyst Ratings for Viridian Therapeutics

Data brought to you by Benzinga APIs

FAQ

Q

What is the target price for Viridian Therapeutics (VRDN) stock?

A

The latest price target for Viridian Therapeutics (NASDAQ:VRDN) was reported by RBC Capital on September 19, 2024. The analyst firm set a price target for $44.00 expecting VRDN to rise to within 12 months (a possible 95.56% upside). 34 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Viridian Therapeutics (VRDN)?

A

The latest analyst rating for Viridian Therapeutics (NASDAQ:VRDN) was provided by RBC Capital, and Viridian Therapeutics reiterated their outperform rating.

Q

When was the last upgrade for Viridian Therapeutics (VRDN)?

A

There is no last upgrade for Viridian Therapeutics

Q

When was the last downgrade for Viridian Therapeutics (VRDN)?

A

The last downgrade for Viridian Therapeutics Inc happened on May 9, 2024 when Ladenburg Thalmann changed their price target from N/A to N/A for Viridian Therapeutics Inc.

Q

When is the next analyst rating going to be posted or updated for Viridian Therapeutics (VRDN)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Viridian Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Viridian Therapeutics was filed on September 19, 2024 so you should expect the next rating to be made available sometime around September 19, 2025.

Q

Is the Analyst Rating Viridian Therapeutics (VRDN) correct?

A

While ratings are subjective and will change, the latest Viridian Therapeutics (VRDN) rating was a reiterated with a price target of $44.00 to $44.00. The current price Viridian Therapeutics (VRDN) is trading at is $22.50, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch